IOVANCE BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-09-30 was $47.52M, a 76.61% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-06-30 was $152.43M.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for the quarter ending 2024-03-31 was $197.36M, a 24.12% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for fiscal 2025 was $306.31M, a 22.90% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for fiscal 2024 was $397.30M, a 14.24% decline from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for fiscal 2023 was $463.28M, a 144.47% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, other for fiscal 2022 was $189.50M, a 6.72% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2025-12-31 | $306.31M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $397.30M 10-K · filed 2026-02-24 |
| 2024-09-30 | $47.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $397.31M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $152.43M 10-Q · filed 2024-08-08 | $552.97M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $197.36M 10-Q · filed 2024-05-09 | $400.54M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $463.28M 10-K · filed 2026-02-24 |
| 2023-09-30 | $203.18M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2023-03-31 | $260.10M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $189.50M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $203.16M 10-K · filed 2024-02-28 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $44.01M 10-K · filed 2019-02-28 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | |
| 2015-09-30 | $162.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | |
| 2015-03-31 | $68.31M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $32.24M 10-K · filed 2017-03-09 | |
| 2013-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $5.89M 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | |
| 2012-12-31 | $67.92K 10-K · filed 2014-03-28 | |
| 2010-12-31 | $1.91M 10-K · filed 2014-03-28 | |
| 2007-12-31 | $53.00K 10-K · filed 2013-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |